Literature DB >> 9278201

Chloroquine-induced pruritus in malaria fever: contribution of malaria parasitaemia and the effects of prednisolone, niacin, and their combination, compared with antihistamine.

R A Adebayo1, G G Sofowora, O Onayemi, S J Udoh, A A Ajayi.   

Abstract

AIMS: Chloroquine treatment of malaria fever, results in a generalized pruritus of unknown mechanism in up to 60% of adult Africans, by contrast pruritus is unusual in Caucasians following chloroquine use.
METHODS: We conducted a double-blind, randomized, parallel group study to examine and compare the antipruritic effects of promethazine, niacin, prednisolone and their combination on pruritus induced by chloroquine, in 28 historical itching patients with parasitologically proven malaria fever. We also evaluated the role of the antecedent malaria parasite density in the severity of chloroquine pruritus intensity.
RESULTS: The concurrent administration of chloroquine (2.1 g base total dose) with prednisolone caused a statistically significant reduction in the pruritus AUC (0, 72 h) (P < 0.001 ANOVA) compared with the antihistamine promethazine alone. The areas under the pruritus intensity-time curve were promethazine 105 +/- 28 (units h), niacin 76 +/- 22, prednisolone 28 +/- 24, and prednisolone and niacin 34 +/- 17 (P < 0.001 ANOVA). The 95% confidence interval for the difference in the pruritus AUC between prednisolone and promethazine was 8.4 to 145.6 units h. There was a statistically significant and positive correlation between the pruritus intensity (AUC 0, 72 h) and the malaria parasite load in the itching subjects, not receiving prednisolone (n = 9) (r = 0.73, P = 0.026 ANOVA).
CONCLUSION: A single oral dose of prednisolone (10 mg) may be preferable to the antihistamine promethazine (25 mg) as an antipruritic agent for concurrent prescription with chloroquine in individuals predisposed to severe itching. Malaria parasite clearance and clinical amelioration were unaffected by any of the treatments.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9278201      PMCID: PMC2042828          DOI: 10.1046/j.1365-2125.1997.00612.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

Review 1.  Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review.

Authors:  Sergio Marin; Alba Martin Val; Maite Bosch Peligero; Cristina Rodríguez-Bernuz; Ariadna Pérez-Ricart; Laia Vilaró Jaques; Roger Paredes; Josep Roca; Carles Quiñones
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-21

2.  Pharmacokinetic properties of azithromycin in pregnancy.

Authors:  Sam Salman; Stephen J Rogerson; Kay Kose; Susan Griffin; Servina Gomorai; Francesca Baiwog; Josephine Winmai; Josin Kandai; Harin A Karunajeewa; Sean J O'Halloran; Peter Siba; Kenneth F Ilett; Ivo Mueller; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2009-10-26       Impact factor: 5.191

3.  Chloroquine-induced Pruritus.

Authors:  S E Aghahowa; H O Obianwu; A O Isah; I M Arhewoh
Journal:  Indian J Pharm Sci       Date:  2010-05       Impact factor: 0.975

4.  Red ginseng extract blocks histamine-dependent itch by inhibition of H1R/TRPV1 pathway in sensory neurons.

Authors:  Yongwoo Jang; Wook-Joo Lee; Gyu-Sang Hong; Won-Sik Shim
Journal:  J Ginseng Res       Date:  2015-01-22       Impact factor: 6.060

Review 5.  Systemic toxicity of chloroquine and hydroxychloroquine: prevalence, mechanisms, risk factors, prognostic and screening possibilities.

Authors:  Romain Muller
Journal:  Rheumatol Int       Date:  2021-04-24       Impact factor: 2.631

6.  The utilization of hydroxychloroquine to reduce the main signs and symptoms of COVID-19 patients, a cross-sectional study.

Authors:  Salem Alsuwaidan; Ziad A Memish; Faisal Alaklobi; Kholood Khan; Hamdan N Alajami
Journal:  Ann Med Surg (Lond)       Date:  2021-09-16

Review 7.  FIRST REPORTS OF CLINICAL PHARMACOKINETICS IN NIGERIA.

Authors:  O S Michael
Journal:  Ann Ib Postgrad Med       Date:  2015-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.